Literature DB >> 3011678

Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium.

M J Rogers, J Cohen.   

Abstract

Polymyxins are cyclic polypeptide antibiotics. In addition to their bactericidal activity they bind lipid A and neutralize the biological effects of bacterial endotoxin. We have studied the three available polymyxin preparations: polymyxin B sulphate (PB), colistin sulphate (CS) and colistin sulphomethate sodium (CMS), and compared their endotoxin binding capacity at equivalent therapeutic dosage. Each polymyxin was bound to a column of Sepharose 4B and challenged with 5 micrograms of endotoxin from Escherichia coli O127:B8. Recovery of endotoxin in the eluate was measured by a quantitative Limulus lysate microassay. PB and CS bound 94% of the challenge dose, CMS 89% and the control column (Sepharose alone) 24%. These results suggest that parenteral CMS (the least toxic polymyxin) retains useful anti-endotoxin capacity, and that in neutropenic patients, oral polymyxin may exert both anti-endotoxin and antimicrobial effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011678     DOI: 10.1007/bf01644448

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Modification of human neutrophil response to endotoxin with polymyxin B sulfate.

Authors:  J J Corrigan; O E Sieber; H Ratajczak; B B Bennett
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

2.  Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate.

Authors:  J J Corrigan; B M Bell
Journal:  J Lab Clin Med       Date:  1971-05

3.  Removal of gram-negative endotoxin from solutions by affinity chromatography.

Authors:  A C Issekutz
Journal:  J Immunol Methods       Date:  1983-07-29       Impact factor: 2.303

4.  Infection in neutropenia: Anti-endotoxin effect of polymyxin.

Authors:  R M Bannatyne; R Cheung
Journal:  Anticancer Res       Date:  1982 Jul-Aug       Impact factor: 2.480

5.  Observations on the measurement and evaluation of endotoxemia by a quantitative limulus lysate microassay.

Authors:  J Cohen; J S McConnell
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

6.  Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B.

Authors:  J Cohen; M Aslam; C D Pusey; C J Ryan
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

7.  Neutralization of endotoxin toxicity in chick embryos by antibiotics.

Authors:  D Rifkind; J D Palmer
Journal:  J Bacteriol       Date:  1966-10       Impact factor: 3.490

8.  Neurotoxic and nephrotoxic effects of colistin in patients with renal disease.

Authors:  E Wolinsky; J D Hines
Journal:  N Engl J Med       Date:  1962-04-12       Impact factor: 91.245

9.  Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study.

Authors:  H F Guiot; P J van den Broek; J W van der Meer; R van Furth
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia.

Authors:  R A Storring; B Jameson; T J McElwain; E Wiltshaw
Journal:  Lancet       Date:  1977-10-22       Impact factor: 79.321

View more
  3 in total

1.  Bordetella Pertussis Toxin does not induce the release of pro-inflammatory cytokines in human whole blood.

Authors:  Christina Bache; Ingo Spreitzer; Bjoern Becker; Bettina Loeschner; Ute Rosskopf; Kay-Martin Hanschmann; Michael Schwanig; Christian K Schneider; Bernhard Lieb; Thomas Montag
Journal:  Med Microbiol Immunol       Date:  2012-04-15       Impact factor: 3.402

Review 2.  Endotoxemia: methods of detection and clinical correlates.

Authors:  J C Hurley
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 3.  Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Authors:  Cordula Koerner-Rettberg; Manfred Ballmann
Journal:  Core Evid       Date:  2014-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.